This site is intended for healthcare professionals
News

BMS receives approval for Abecma , the first CAR T therapy approved for the treatment of multiple myeloma in Japan.

Read time: 1 mins
Published:21st Jan 2022
Bristol-Myers Squibb K.K. announced that Japan’s Ministry of Health, Labour and Welfare has approved Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and have either experienced disease progression on the last therapy or relapse after the last therapy.

Abecma is the first CAR T cell therapy approved for the treatment of R/R multiple myeloma in Japan. With this approval, Bristol Myers Squibb is now the only company in Japan with two approved CAR T cell therapies—the CD19-directed Breyanzi, which received approval in March 2021, and the BCMA-directed Abecma.

The approval is based on efficacy and safety data sourced from the global Phase II Study BB2121-MM-001 conducted in Japan, the U.S., the EU, and Canada, and the Phase 1 Study CRB-401 in the U.S.

Condition: Multiple Myeloma
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.